Log In
Print this Print this

HemaMax (NMIL 12-1)

  Manage Alerts
Collapse Summary General Information
Company Neumedicines Inc.
DescriptionRecombinant human IL-12
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationPoisoning
Indication DetailsTreat acute radiation syndrome (ARS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today